Wish to keep on high of the science and politics driving biotech at this time? Join to get our biotech publication in your inbox.
AI continues to attract large capital and new use instances in biopharma: Take Prometheus’ $12 billion increase to construct “synthetic common engineers,” or Abridge’s new partnerships with Eli Lilly and Nvidia, which goals partially to optimize the medical trial recruitment course of.
Plus, a nonprofit buys a shelved drug for a pediatric leukemia with plans to distribute it free of charge.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
